Article

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial

2021-10-25

Abstract excerpt

<h4>Introduction</h4> Event free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30-50%, with 5-year survival for adult patients only 20%. A large proportion of patients with newly diagnosed and relapsed ALL harbour somatic mutations that activate the RAS-signalling cascade. Steroids are a backbone of all induction blocks of ALL therapy, with prec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 86cd10b2-6d4f-53cb-9fb5-87a28574f714
DOI: 10.1101/2021.10.22.21265327

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trialDOI 10.1101/2021.10.22.21265327Read

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.Semantic proximity Read

Molecular and cellular mechanisms of chemoresistance in paediatric pre–B cell acute lymphoblastic leukaemiaSemantic proximity Read

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.Semantic proximity Read

MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemiaSemantic proximity Read

Toxicity profile and treatment delays in <scp>NOPHO ALL</scp>2008—comparing adults and children with Philadelphia chromosome‐negative acute lymphoblastic leukemiaSemantic proximity Read

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?Semantic proximity Read

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 StudySemantic proximity Read

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Semantic proximity Read

Direct STAT3 and STAT5 Inhibition Overcomes Treatment Resistance in a Murine-Derived in vitro Model of Acute Lymphoblastic Leukaemia Driven by <italic>ETV6::JAK2</italic>.Semantic proximity Read

Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia.Semantic proximity Read

The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?Semantic proximity Read

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.Semantic proximity Read